🧾 What This Document Is

This is a PRE 14A, a "preliminary proxy statement." Think of it as the official invitation and agenda for REGENXBIO's upcoming annual shareholder meeting. It's a draft that will be finalized after SEC review. Its purpose is to give shareholders the information they need to vote on key company decisions.

🏢 What The Company Does

👉 In simple terms, REGENXBIO is a biotech company trying to cure diseases by replacing faulty genes. They develop one-time gene therapy treatments designed to last a lifetime. They're not a big, profitable drug seller yet; they're a clinical-stage company, meaning their main products are still being tested in people.

📋 The Shareholder Meeting Agenda (The Five Proposals)

The core of this document is asking shareholders to vote on five items at the May 29, 2026 meeting:

Elect Three Directors: Vote to re-elect Jean Bennett, Jerry Karabelas, and Daniel Tassé to the board. Their bios highlight deep expertise in gene therapy, biotech leadership, and commercial operations.
Ratify the Auditor: Approve PricewaterhouseCoopers LLP (PwC) as the company's accountant for 2026. They've been the auditor since 2015.
Advisory Vote on Executive Pay: A non-binding "say-on-pay" vote where shareholders express their opinion on how the top executives are compensated.
Approve a Stock Option Exchange for Non-Executive Employees: This is a major new proposal. Employees can voluntarily swap their "underwater" stock options (where the company's current stock price is below the option's strike price, making them worthless) for a smaller number of new options with a strike price set at today's lower market value. This refreshes incentives.
Approve a Stock Option Exchange for Executive Employees: Same concept as above, but specifically for the executive team (excluding the CEO and directors).

👉 Why it matters: Proposals 4 and 5 are the most significant new items. This is a common move at struggling biotechs to retain key talent when the stock has fallen, offering them a fresh chance to profit if the stock recovers.

🚀 Business & Clinical Highlights from 2025

The company recaps its progress, which provides context for the votes:

Key Programs: Enrolled over 1,200 patients in pivotal trials for wet AMD (with partner AbbVie) and for Duchenne Muscular Dystrophy (RGX-202).
A Setback: Its MPS II program (RGX-121) hit a major snag. The FDA placed it on clinical hold and then rejected its application for approval in February 2026 due to safety concerns. The company is working on a response.
Partnerships & Cash: Raised $110M from a deal with Nippon Shinyaku and $150M from a royalty bond. Ended 2025 with $240.9 million in cash.

🤝 Governance & The Board

The board has 10 members. The CEO (Curran Simpson) and Chairman (Kenneth Mills) are not considered independent. The rest are independent. The board emphasizes its active oversight of strategy, risk management, and its commitment to diversity.

💰 Director & Executive Compensation

Directors: Non-employee directors get about $325K-$360K in total annual compensation, mix of cash fees and stock awards.
Executive Pay: Detailed tables show compensation for named executives. The Compensation Committee, advised by an independent consultant, sets pay based on peer group analysis.

🔮 What's Next & The Vote

Shareholders must decide by May 29, 2026. The board recommends voting "FOR" all five proposals. The vote on the stock option exchanges is crucial for employee morale and retention, while the director election and auditor ratification are more routine governance items.

⚖️ Big Picture

👍 Strengths: Strong gene therapy pipeline with late-stage trials, experienced board and management, strategic partnerships providing cash, and proactive steps to retain talent via the option exchange.
⚠️ Risks: Significant regulatory setback with the RGX-121 rejection and clinical hold, the inherent high risk and expense of clinical-stage biotech, and dependence on partnership funding and trial successes.

🧠 The Analogy

REGENXBIO is like a marathon runner with a promising but tiring race ahead. They have good training and support (cash, partnerships), but recently stumbled at a water station (the FDA setback). Their proposed stock option exchange is like giving the running crew (employees) fresh water bottles (new options) to help them refocus and keep running for the finish line (successful drug approvals).

📇 Key Contacts & People

Curran Simpson: President & Chief Executive Officer (signed the notice)
Board Nominees for Election: Jean Bennett, M.D., Ph.D.; A.N. “Jerry” Karabelas, Ph.D.; Daniel Tassé
Corporate Secretary: (Address for shareholder communications: REGENXBIO Inc., 9804 Medical Center Drive, Rockville, MD 20850, Attention: Corporate Secretary)

🧩 Final Takeaway

This proxy statement centers on refreshing executive and employee incentives through a stock option exchange program, following a significant regulatory setback. It's a sign the company is taking decisive action to maintain morale while navigating challenges in its path to bringing gene therapies to market.

REGENXBIO Inc. — PRE 14A Filing